12 programs. 9 targets. 8 patents. 2 clinical studies.
A validated pipeline of small-molecule programs discovered with MetaScreener and our in-house HPC infrastructure — covering oncology, metabolism, inflammation and drug-resistance indications.
About MetaScreener
The engine behind the pipeline — an in-house suite for virtual screening on supercomputers.
MetaScreener (MS) is a multi-language suite (Shell, Python, Java, C) that orchestrates large-scale computational drug-discovery campaigns on HPC infrastructures.
It integrates multiple methods, dispatches jobs through parallel task scheduling, and automatically post-processes results into ranked tables, graphs and PyMOL sessions:
- Molecular docking
- Pharmacophore screening
- Molecular modelling
- Consensus aggregation across methods
Open source: github.com/bio-hpc/metascreener
MetaScreener workflow
Pipeline 2025
Selected programs discovered with MetaScreener — activity, development stage and IP status. Selected highlights; many additional success stories not listed here.
| Target | Compound type / MoA | Activity | In silico | In vitro | In vivo | Clinical | IP status |
|---|---|---|---|---|---|---|---|
| Fascin | FDA · Imipramine | 20 µM | ✓ | ✓ | ✓ | Started Murcia 2022 | Patent licensed 2023open to new licensing |
| Fascin | FDA · Raltegravir | 20 µM | ✓ | ✓ | ✓ | Requested | Patent granted |
| Fascin | Novel Chemical Entity | 20 µM | ✓ | ✓ | In progress | Requested | Patent filed |
| Hepsin | FDA · Venetoclax | 1 µM | ✓ | ✓ | — | Requested | Patent granted |
| Hepsin | FDA · Suramin | 1 µM | ✓ | ✓ | — | Requested | Patent granted |
| PAD4 | FDA · Gilteritinib | 1 µM | ✓ | ✓ | In progress | Requested | Patent filed |
| Wee1 | Novel Chemical Entity | 20 nM | ✓ | ✓ | — | — | — |
| p38α | Novel Chemical Entity | 26 nM | ✓ | ✓ | — | — | — |
| DDR1 | Novel Chemical Entity | 3 nM | ✓ | ✓ | — | — | — |
| human sEH | Novel Chemical Entity | 100 nM | ✓ | ✓ | In progress | — | In patent-filing process |
| ABCC3 | Novel Chemical Entity | 1 µM | ✓ | ✓ | — | — | — |
| Pancreatic lipase | Natural · Silibinin | Similar to orlistat | ✓ | ✓ | — | Started Murcia 2023 | Patent granted |
Selected case studies
Three representative programs from the pipeline — from repurposing wins to nanomolar novel chemical entities.
Repurposing · Patent licensed
Fascin inhibitors — colorectal cancer metastasis
Structure-based discovery of the FDA-approved antidepressant imipramine and the antiviral raltegravir as potent Fascin1 inhibitors that block invasion of colorectal tumour cells in vitro and in vivo. Patent licensed; clinical study started in Murcia (2022).
DOI 10.3390/cancers13040861 →Natural product · Clinical study
Silibinin — pancreatic lipase inhibitor
Identification of the thistle-milk component silibinin as a potent inhibitor of pancreatic lipase (profile similar to orlistat), with potential implications on weight loss. Patent filed; clinical study started in Murcia (2023).
DOI 10.1016/j.jff.2021.104479 →Target-based programs
Hepsin · PAD4 · Wee1 · DDR1 · p38α · sEH · ABCC3
Multiple programs delivering novel chemical entities with activities as low as 3 nM (DDR1) and 20 nM (Wee1). Six patents filed or in preparation, covering indications in oncology, immunology, inflammation, metabolism and drug-resistance mechanisms.
Partner with us
We are actively seeking biotech and pharmaceutical partners across three tracks. All commercial agreements are channelled through UCAM’s Technology Transfer Office (OTRI).
Licensing
Patents available for licensing or sub-licensing across multiple targets and indications.
Co-development
Joint pre-clinical and clinical development of novel chemical entities with nanomolar activities.
Clinical-trial investment
Investment opportunities for ongoing clinical studies in colorectal cancer and weight-loss.
Contact: Prof. Horacio Pérez-Sánchez · hperez@ucam.edu
European Project Horizon 2020 SC1-BHC-02-2019 [REVERT, ID: 848098] · Fundación Séneca, CCIRM [20988/PI/18] · Ministerio de Ciencia e Innovación · Supercomputing resources: BSC (Spain), NLHPC (Chile), PSNC (Poland).